MX2017009153A - Proteinas de fusion de citoquinas. - Google Patents

Proteinas de fusion de citoquinas.

Info

Publication number
MX2017009153A
MX2017009153A MX2017009153A MX2017009153A MX2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A
Authority
MX
Mexico
Prior art keywords
fusion proteins
cytokine fusion
nucleic acid
acid molecules
present
Prior art date
Application number
MX2017009153A
Other languages
English (en)
Inventor
Sahin Ugur
Kreiter Sebastian
GIESEKE Friederike
Backer Ronald
Kontermann Roland
Pfizenmaier Klaus
FELLERMAIER Sina
MÜLLER Dafne
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Publication of MX2017009153A publication Critical patent/MX2017009153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

La presente invención se relaciona a proteínas de fusión de citoquinas y a moléculas de ácido nucleico que codifican dichas proteínas de fusión de citoquinas. La presente invención además se relaciona a las células, organismos no humanos, composiciones farmacéuticas y kits que incluyen proteínas de fusión de citoquinas o las moléculas de ácido nucleico que las codifican, así como a su utilización como medicamentos.
MX2017009153A 2015-01-15 2016-01-15 Proteinas de fusion de citoquinas. MX2017009153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/050682 WO2016112983A1 (en) 2015-01-15 2015-01-15 Cytokine fusion proteins
PCT/EP2016/050773 WO2016113395A1 (en) 2015-01-15 2016-01-15 Cytokine fusion proteins

Publications (1)

Publication Number Publication Date
MX2017009153A true MX2017009153A (es) 2018-02-01

Family

ID=52394237

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009153A MX2017009153A (es) 2015-01-15 2016-01-15 Proteinas de fusion de citoquinas.
MX2021010668A MX2021010668A (es) 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010668A MX2021010668A (es) 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas.

Country Status (11)

Country Link
US (2) US10301368B2 (es)
EP (1) EP3245223B1 (es)
JP (1) JP6813491B2 (es)
CN (2) CN107428842B (es)
AU (1) AU2016207955B2 (es)
BR (1) BR112017013956B8 (es)
CA (1) CA2971950A1 (es)
HK (2) HK1246316A1 (es)
MX (2) MX2017009153A (es)
NZ (1) NZ733266A (es)
WO (2) WO2016112983A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
JP7260477B2 (ja) * 2017-02-27 2023-04-18 シャタック ラボ，インコーポレイテッド Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
AU2018229278A1 (en) * 2017-02-28 2019-10-17 Sanofi Therapeutic RNA
US11142558B2 (en) 2017-04-06 2021-10-12 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
CA3069017A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof
CA3087476A1 (en) * 2018-01-10 2019-07-18 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
BR112020024179A2 (pt) 2018-06-01 2021-03-30 Sanofi Terapia de combinação para tratar infecção por vírus da hepatite b
AU2019362902A1 (en) * 2018-10-17 2021-04-29 Albert Einstein College Of Medicine Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc)
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
US20230174618A1 (en) * 2019-10-08 2023-06-08 Fred Hutchinson Cancer Center Engineered trimeric cd70 proteins and uses thereof
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
SI2310509T1 (sl) 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
CN102421913A (zh) * 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CA2868366C (en) * 2012-04-24 2017-10-03 Nordischer Maschinenbau Rud. Baader Gmbh + Co. Kg A fish corral
WO2014145355A1 (en) * 2013-03-15 2014-09-18 Stone Geoffrey W Composition comprised of antigen linked to a tnf superfamily ligand

Also Published As

Publication number Publication date
CN107428842B (zh) 2021-10-01
BR112017013956A8 (pt) 2019-04-02
US20180002392A1 (en) 2018-01-04
US20190276511A1 (en) 2019-09-12
EP3245223B1 (en) 2020-03-04
CN113801241A (zh) 2021-12-17
JP2018503379A (ja) 2018-02-08
JP6813491B2 (ja) 2021-01-13
AU2016207955A1 (en) 2017-07-20
NZ733266A (en) 2022-04-29
BR112017013956A2 (pt) 2018-01-16
HK1246316A1 (zh) 2018-09-07
HK1246315A1 (zh) 2018-09-07
CN107428842A (zh) 2017-12-01
MX2021010668A (es) 2021-09-28
US10301368B2 (en) 2019-05-28
AU2016207955B2 (en) 2020-05-28
CA2971950A1 (en) 2016-07-21
BR112017013956B8 (pt) 2024-02-06
WO2016113395A1 (en) 2016-07-21
EP3245223A1 (en) 2017-11-22
WO2016112983A1 (en) 2016-07-21
US10808019B2 (en) 2020-10-20
BR112017013956B1 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
MX2021010668A (es) Proteinas de fusion de citoquinas.
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
AU2017248555B2 (en) Closed nucleic acid structures
MX2019000205A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
WO2015109124A3 (en) Immunomodulatory agents
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX371018B (es) Polipéptidos que tienen actividad de transgalactosilación.
GB2537077A (en) Methods for sequencing nucleic acids
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).